 Home > Medical News > Latest Medical News > AbbVie's IL-23 inhibitor is expected to gain the second indication with EU CHMP support

AbbVie's IL-23 inhibitor is expected to gain the second indication with EU CHMP support

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

hypoxia treatment

pulmonary hypertension treatment drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 15, 2021, AbbVie announced that the European Medicines Agency (EMA) Committee for Medicines for Human Use (CHMP) recommended to approve risankizumab (trade name Skyrizi) as a single drug or in combination with methotrexate (MTX).

Psoriatic arthritis is a heterogeneous, systemic inflammatory disease with hallmark manifestations in multiple systems (including joints and skin)

Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit

This positive opinion of CHMP is supported by two pivotal Phase 3 clinical trials

In terms of safety, the most common adverse reactions associated with risankizumab are upper respiratory tract infections, headaches, fatigue, injection site reactions and ringworm infections

Reference materials:

[1] AbbVie Receives CHMP Positive Opinion for Risankizumab (Skyrizi®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU).

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express is supported by EU CHMP, AbbVie IL-23 inhibitor is expected to gain the second indication

11-05

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

AbbVie's IL-23 inhibitor is expected to gain the second indication with EU CHMP support

Related Articles

Express is supported by EU CHMP, AbbVie IL-23 inhibitor is expected to gain the second indication